NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

AMRN

Amarin Corp ADR

Jul 11 • 04:00PM ET

16.93

Dollar change -0.39
Percentage change -2.25	%

Healthcare • Drug Manufacturers - General • Ireland • NASD

Peers: GILD REGN VRTX NBIX SRPT MDGL DVAX VKTX AKBA ITCI

| Held by: SPDW GWX IBBQ BIB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.27	Insider Own	0.42%	Shs Outstand	20.72M	Perf Week	1.20%
Market Cap	350.79M	Forward P/E	-	EPS next Y	-1.24	Insider Trans	0.00%	Shs Float	20.63M	Perf Month	32.06%
Enterprise Value	76.64M	PEG	-	EPS next Q	-0.25	Inst Own	17.56%	Short Float	2.17%	Perf Quarter	84.70%
Income	-87.79M	P/S	1.64	EPS this Y	46.42%	Inst Trans	0.67%	Short Ratio	3.53	Perf Half Y	53.91%
Sales	214.21M	P/B	0.74	EPS next Y	42.15%	ROA	-12.15%	Short Interest	0.45M	Perf YTD	74.54%
Book/sh	22.86	P/C	1.24	EPS next 5Y	39.37%	ROE	-17.22%	52W High	17.49 -3.20%	Perf Year	20.93%
Cash/sh	13.61	P/FCF	-	EPS past 3/5Y	- -24.69%	ROIC	-18.23%	52W Low	7.08 139.12%	Perf 3Y	-45.74%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-26.80% -11.92%	Gross Margin	33.62%	Volatility	4.11% 6.70%	Perf 5Y	-87.87%
Dividend TTM	-	EV/Sales	0.36	EPS Y/Y TTM	-65.68%	Oper. Margin	-44.26%	ATR (14)	0.88	Perf 10Y	-65.45%
Dividend Ex-Date	-	Quick Ratio	2.55	Sales Y/Y TTM	-22.93%	Profit Margin	-40.99%	RSI (14)	70.70	Recom	4.33
Dividend Gr. 3/5Y	- -	Current Ratio	3.53	EPS Q/Q	-57.14%	SMA20	10.04%	Beta	0.86	Target Price	10.50
Payout	-	Debt/Eq	0.02	Sales Q/Q	-25.33%	SMA50	31.47%	Rel Volume	0.81	Prev Close	17.32
Employees	275	LT Debt/Eq	0.02	Earnings	May 07 BMO	SMA200	52.28%	Avg Volume	127.05K	Price	16.93
IPO	Apr 01, 1993	Option/Short	Yes / Yes	EPS/Sales Surpr.	94.81% -19.14%	Trades		Volume	102,660	Change	-2.25%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-23	Resumed	JP Morgan	Underweight
Oct-25-23	Downgrade	Jefferies	Buy → Hold	$3 → $1
Jan-06-23	Upgrade	Jefferies	Hold → Buy	$1.30 → $3
May-06-22	Downgrade	JP Morgan	Neutral → Underweight
May-05-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$10 → $3
May-05-22	Downgrade	H.C. Wainwright	Buy → Neutral	$10 → $3
May-04-22	Downgrade	Northland Capital	Outperform → Market Perform
May-12-21	Downgrade	Goldman	Neutral → Sell	$6 → $5
Sep-29-20	Resumed	JP Morgan	Neutral
Aug-26-20	Initiated	Piper Sandler	Overweight	$21
May-05-20	Initiated	Northland Capital	Outperform	$15
Mar-31-20	Upgrade	Oppenheimer	Underperform → Perform
Mar-31-20	Downgrade	Jefferies	Buy → Hold	$30 → $4
Mar-31-20	Downgrade	Goldman	Buy → Neutral
Mar-13-20	Upgrade	Goldman	Neutral → Buy	$28
Mar-02-20	Initiated	Cowen	Outperform	$23
Feb-18-20	Upgrade	Citigroup	Neutral → Buy	$27 → $24
Jan-06-20	Initiated	JP Morgan	Neutral	$22
Dec-16-19	Downgrade	Stifel	Buy → Hold
Nov-20-19	Initiated	Oppenheimer	Underperform	$7

Show Previous Ratings

Jul-11-25 12:12PM	FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill (Zacks)
Jul-10-25 12:10PM	KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up (Zacks)
11:09AM	RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data (Zacks)
09:11AM	KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally? (Zacks)
Jul-09-25 12:26PM	PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study (Zacks)
09:40AM	Loading…
Jul-02-25 09:40AM	Are Medical Stocks Lagging Amarin (AMRN) This Year? (Zacks)
Jul-01-25 09:17AM	Moderna Stock Gains on Encouraging Flu Vaccine Data (Zacks)
Jun-27-25 10:00AM	Best Momentum Stock to Buy for June 27th (Zacks)
Jun-25-25 11:06AM	Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU (Zacks)
10:02AM	Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag (Zacks)
09:28AM	Amarin (AMRN) Soars 27.3%: Is Further Upside Left in the Stock? (Zacks)
Jun-24-25 07:05AM	RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE (GlobeNewswire) +27.26%
07:00AM	Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA (Icosapent Ethyl) in Europe (GlobeNewswire)
Jun-23-25 12:34PM	SNY Gets CHMP Nod for Expanded Use of Sarclisa in Multiple Myeloma (Zacks)
Jun-20-25 09:46AM	Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid (Zacks) -5.93%
11:11AM	Loading…
Jun-19-25 11:11AM	Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma (Zacks)
Jun-18-25 10:51AM	Bayer Seeks FDA Approval for MRI Contrast Agent Gadoquatrane (Zacks)
Jun-16-25 09:55AM	Amarin (AMRN) Now Trades Above Golden Cross: Time to Buy? (Zacks)
09:40AM	Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-10-25 12:00PM	Amarin (AMRN) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
10:00AM	Best Momentum Stocks to Buy for June 10th (Zacks)
09:08AM	Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM (Zacks)
06:50AM	New Strong Buy Stocks for June 10th (Zacks)
Jun-06-25 11:52AM	KURA Stock Rises More Than 15% This Past Week: Here's Why (Zacks) +7.34%
Jun-05-25 01:03PM	Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio? (Zacks)
12:55PM	Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success (Zacks)
Jun-04-25 12:17PM	JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate Cancer (Zacks)
10:46AM	SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease (Zacks)
Jun-03-25 11:14AM	Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug (Zacks)
09:43AM	Amgen's Imdelltra Cuts Lung Cancer Death Risk by 40% in Phase III (Zacks)
11:58AM	Loading…
Jun-02-25 11:58AM	Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines (Zacks)
May-30-25 08:59AM	IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus (Zacks)
May-29-25 11:53AM	ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study (Zacks)
11:44AM	BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications (Zacks)
10:50AM	CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer (Zacks)
09:40AM	Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year? (Zacks)
May-28-25 11:09AM	RCKT Stock Tanks on Patient Death in Danon Disease Study (Zacks)
11:07AM	TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate (Zacks)
10:43AM	VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval (Zacks)
May-27-25 10:46AM	AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer (Zacks)
May-26-25 11:44AM	GSK Gets CHMP Nod for Blenrep Combos in Multiple Myeloma (Zacks)
11:25AM	SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease (Zacks)
May-23-25 10:01AM	Bayer Gets CHMP Nod for Eylea 8 mg in the EU for 2 Major Eye Diseases (Zacks)
09:57AM	EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort (Zacks)
May-21-25 12:33PM	Bayer Begins Phase I Study on BAY 3670549 in Atrial Fibrillation (Zacks)
09:50AM	ARMP Soars 72% in a Month Following Infectious Disease Study Success (Zacks)
May-20-25 11:50AM	CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies (Zacks)
May-08-25 12:07PM	Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y (Zacks) +5.21%
03:07AM	Amarin Corp PLC (AMRN) Q1 2025 Earnings Call Highlights: Strategic Global Expansion Amidst ... (GuruFocus.com)
May-07-25 11:01AM	Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript (Seeking Alpha)
07:32AM	Amarin: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Amarin Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-03-25 03:02AM	Standex International Corp (SXI) Q3 2025 Earnings Call Highlights: Record Margins and Strategic ... (GuruFocus.com)
Apr-29-25 04:15PM	Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Apr-28-25 04:15PM	Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 (GlobeNewswire)
Apr-09-25 07:30AM	Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change (GlobeNewswire) +6.63%
Apr-07-25 07:30AM	Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors (GlobeNewswire)
Mar-31-25 08:00AM	Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist (GlobeNewswire)
Mar-19-25 12:45PM	Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance (Business Wire) +6.31%
07:30AM	New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo (GlobeNewswire)
Mar-13-25 03:02AM	Amarin Corp PLC (AMRN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Expanding ... (GuruFocus.com)
Mar-12-25 12:45PM	Amarin Plc (AMRN) Q4 2024 Earnings Call Transcript (Motley Fool) -14.94%
07:20AM	Amarin: Q4 Earnings Snapshot (Associated Press Finance)
07:01AM	Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program (GlobeNewswire)
07:00AM	Amarin Reports Fourth Quarter Financial Results & Business Update and Announces Important Corporate Action (GlobeNewswire)
Feb-27-25 09:00AM	Amarin Marks Key Milestone for VASCEPA /VAZKEPA (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering (GlobeNewswire)
Feb-25-25 08:00AM	Amarin Receives National Reimbursement for VAZKEPA in Austria (GlobeNewswire)
Feb-19-25 08:30AM	Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025 (GlobeNewswire)
Dec-16-24 07:00AM	Amarin Receives National Reimbursement for VAZKEPA in Italy (GlobeNewswire)
Dec-13-24 09:00AM	Amarin Appoints Peter Fishman Chief Financial Officer (GlobeNewswire)
Nov-19-24 09:35AM	After Plunging -19.13% in 4 Weeks, Here's Why the Trend Might Reverse for Amarin (AMRN) (Zacks) +5.53%
Nov-11-24 08:00AM	Investigators to Present New REDUCE-IT Subanalysis of VASCEPA /VAZKEPA (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association's (AHA) Annual Scientific Sessions (GlobeNewswire)
Nov-01-24 03:19AM	Amarin Corp PLC (AMRN) Q3 2024 Earnings Call Highlights: Navigating Revenue Declines Amid ... (GuruFocus.com)
Oct-31-24 02:00AM	Amarin Plc (AMRN) Q3 2024 Earnings Call Transcript (Motley Fool)
Oct-30-24 05:21PM	Amarin: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-29-24 09:16AM	Amarin Corp PLC (AMRN) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Oct-09-24 03:32PM	Amarin Corp PLC (AMRN) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges and ... (GuruFocus.com)
Oct-01-24 08:00AM	Amarin Announces Two Upcoming Investor Events (GlobeNewswire)
Sep-09-24 07:30AM	Research Highlighting the Clinical Impact of VASCEPA /VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting (GlobeNewswire)
Aug-22-24 08:30AM	Latest Research Highlighting VASCEPA /VAZKEPA (icosapent ethyl) REDUCE-IT Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress (GlobeNewswire) -5.09%
Aug-01-24 12:59PM	Amarin (AMRN) Stock Down Despite Q2 Earnings & Revenues Beat (Zacks) -8.90%
Jul-31-24 02:15PM	Amarin Plc (AMRN) Q2 2024 Earnings Call Transcript (Motley Fool) -12.87%
07:00AM	Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-29-24 02:26PM	3 Breakthrough Stocks Under $10 Set for Massive Upside (InvestorPlace)
Jul-17-24 04:15PM	Amarin Receives National Reimbursement for VAZKEPA (icosapent ethyl) in Portugal (GlobeNewswire)
08:00AM	Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 (GlobeNewswire)
Jul-08-24 07:30AM	Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) (GlobeNewswire)
Jun-04-24 07:30AM	Amarin Board of Directors Announces CEO Transition (GlobeNewswire) -17.91%
May-28-24 08:15AM	Amarin Receives National Reimbursement for VAZKEPA (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. (GlobeNewswire)
May-06-24 08:00AM	Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference (GlobeNewswire) +7.69%
May-03-24 10:16AM	Amarin Corporation plc (NASDAQ:AMRN) Q1 2024 Earnings Call Transcript (Insider Monkey)
09:40AM	Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? (Zacks)
May-01-24 12:35PM	Amarin's (AMRN) Q1 Earnings and Revenues Surpass Estimates (Zacks) -8.86%
11:54AM	AMRN Stock Earnings: Amarin Corp Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
11:00AM	Amarin Plc (AMRN) Q1 2024 Earnings Call Transcript (Motley Fool)
08:35AM	Amarin Corp PLC (AMRN) Q1 2024 Earnings: Navigating Challenges with Strategic Focus (GuruFocus.com)
07:30AM	Amarin: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Amarin Reports First Quarter 2024 Business Update and Financial Results (GlobeNewswire)
Apr-24-24 02:00PM	Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event (GlobeNewswire)

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Berg Aaron	President and CEO	Aug 02 '24	Buy	0.64	160,000	102,400	805,380	Aug 05 05:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AMRN

Amarin Corp ADR

Upgrade your FINVIZ experience